nodes	percent_of_prediction	percent_of_DWPC	metapath
Quinidine barbiturate—CHRM2—Tiotropium—chronic obstructive pulmonary disease	0.267	0.458	CbGbCtD
Quinidine barbiturate—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.109	0.187	CbGbCtD
Quinidine barbiturate—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.109	0.187	CbGbCtD
Quinidine barbiturate—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0973	0.167	CbGbCtD
Quinidine barbiturate—Quinine—CYP1A1—chronic obstructive pulmonary disease	0.00276	0.224	CrCbGaD
Quinidine barbiturate—Quinine—CYP1A2—chronic obstructive pulmonary disease	0.00266	0.216	CrCbGaD
Quinidine barbiturate—Quinidine—CYP1A1—chronic obstructive pulmonary disease	0.00242	0.197	CrCbGaD
Quinidine barbiturate—Quinidine—CYP1A2—chronic obstructive pulmonary disease	0.00234	0.189	CrCbGaD
Quinidine barbiturate—Phenobarbital—CYP1A1—chronic obstructive pulmonary disease	0.0011	0.089	CrCbGaD
Quinidine barbiturate—Phenobarbital—CYP1A2—chronic obstructive pulmonary disease	0.00106	0.0858	CrCbGaD
Quinidine barbiturate—SCN5A—Cardiac Progenitor Differentiation—TNNT2—chronic obstructive pulmonary disease	0.000727	0.0533	CbGpPWpGaD
Quinidine barbiturate—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.000692	0.00177	CcSEcCtD
Quinidine barbiturate—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.00069	0.00176	CcSEcCtD
Quinidine barbiturate—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.00069	0.00176	CcSEcCtD
Quinidine barbiturate—Agitation—Montelukast—chronic obstructive pulmonary disease	0.00068	0.00174	CcSEcCtD
Quinidine barbiturate—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000676	0.00173	CcSEcCtD
Quinidine barbiturate—Affect lability—Prednisolone—chronic obstructive pulmonary disease	0.000668	0.00171	CcSEcCtD
Quinidine barbiturate—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000668	0.00171	CcSEcCtD
Quinidine barbiturate—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000667	0.00171	CcSEcCtD
Quinidine barbiturate—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000667	0.00171	CcSEcCtD
Quinidine barbiturate—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000662	0.00169	CcSEcCtD
Quinidine barbiturate—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000659	0.00169	CcSEcCtD
Quinidine barbiturate—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000655	0.00167	CcSEcCtD
Quinidine barbiturate—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000654	0.00167	CcSEcCtD
Quinidine barbiturate—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000653	0.00167	CcSEcCtD
Quinidine barbiturate—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000651	0.00167	CcSEcCtD
Quinidine barbiturate—Cardiac arrest—Prednisolone—chronic obstructive pulmonary disease	0.000646	0.00165	CcSEcCtD
Quinidine barbiturate—Mood swings—Prednisolone—chronic obstructive pulmonary disease	0.000643	0.00164	CcSEcCtD
Quinidine barbiturate—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000643	0.00164	CcSEcCtD
Quinidine barbiturate—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000643	0.00164	CcSEcCtD
Quinidine barbiturate—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000643	0.00164	CcSEcCtD
Quinidine barbiturate—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000643	0.00164	CcSEcCtD
Quinidine barbiturate—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000643	0.00164	CcSEcCtD
Quinidine barbiturate—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000643	0.00164	CcSEcCtD
Quinidine barbiturate—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000643	0.00164	CcSEcCtD
Quinidine barbiturate—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000641	0.00164	CcSEcCtD
Quinidine barbiturate—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000641	0.00164	CcSEcCtD
Quinidine barbiturate—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000641	0.00164	CcSEcCtD
Quinidine barbiturate—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.000641	0.00164	CcSEcCtD
Quinidine barbiturate—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.00064	0.00164	CcSEcCtD
Quinidine barbiturate—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.00064	0.00164	CcSEcCtD
Quinidine barbiturate—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000639	0.00163	CcSEcCtD
Quinidine barbiturate—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000638	0.00163	CcSEcCtD
Quinidine barbiturate—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000638	0.00163	CcSEcCtD
Quinidine barbiturate—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.00063	0.00161	CcSEcCtD
Quinidine barbiturate—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.00063	0.00161	CcSEcCtD
Quinidine barbiturate—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.00063	0.00161	CcSEcCtD
Quinidine barbiturate—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000627	0.0016	CcSEcCtD
Quinidine barbiturate—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000627	0.0016	CcSEcCtD
Quinidine barbiturate—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000625	0.0016	CcSEcCtD
Quinidine barbiturate—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000624	0.0016	CcSEcCtD
Quinidine barbiturate—Oesophagitis—Prednisone—chronic obstructive pulmonary disease	0.000621	0.00159	CcSEcCtD
Quinidine barbiturate—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000616	0.00158	CcSEcCtD
Quinidine barbiturate—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000616	0.00158	CcSEcCtD
Quinidine barbiturate—Ecchymosis—Prednisone—chronic obstructive pulmonary disease	0.000615	0.00157	CcSEcCtD
Quinidine barbiturate—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000607	0.00155	CcSEcCtD
Quinidine barbiturate—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000607	0.00155	CcSEcCtD
Quinidine barbiturate—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000607	0.00155	CcSEcCtD
Quinidine barbiturate—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000607	0.00155	CcSEcCtD
Quinidine barbiturate—Pulmonary oedema—Prednisone—chronic obstructive pulmonary disease	0.000605	0.00155	CcSEcCtD
Quinidine barbiturate—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000605	0.00155	CcSEcCtD
Quinidine barbiturate—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000604	0.00154	CcSEcCtD
Quinidine barbiturate—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000604	0.00154	CcSEcCtD
Quinidine barbiturate—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000604	0.00154	CcSEcCtD
Quinidine barbiturate—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000604	0.00154	CcSEcCtD
Quinidine barbiturate—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000601	0.00154	CcSEcCtD
Quinidine barbiturate—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000601	0.00154	CcSEcCtD
Quinidine barbiturate—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000599	0.00153	CcSEcCtD
Quinidine barbiturate—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000599	0.00153	CcSEcCtD
Quinidine barbiturate—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000599	0.00153	CcSEcCtD
Quinidine barbiturate—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000597	0.00152	CcSEcCtD
Quinidine barbiturate—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	0.000593	0.00152	CcSEcCtD
Quinidine barbiturate—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000592	0.00151	CcSEcCtD
Quinidine barbiturate—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000591	0.00151	CcSEcCtD
Quinidine barbiturate—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000586	0.0015	CcSEcCtD
Quinidine barbiturate—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000582	0.00149	CcSEcCtD
Quinidine barbiturate—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000576	0.00147	CcSEcCtD
Quinidine barbiturate—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000576	0.00147	CcSEcCtD
Quinidine barbiturate—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000573	0.00146	CcSEcCtD
Quinidine barbiturate—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000572	0.00146	CcSEcCtD
Quinidine barbiturate—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000571	0.00146	CcSEcCtD
Quinidine barbiturate—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000568	0.00145	CcSEcCtD
Quinidine barbiturate—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000565	0.00144	CcSEcCtD
Quinidine barbiturate—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000563	0.00144	CcSEcCtD
Quinidine barbiturate—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000563	0.00144	CcSEcCtD
Quinidine barbiturate—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000561	0.00144	CcSEcCtD
Quinidine barbiturate—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000561	0.00144	CcSEcCtD
Quinidine barbiturate—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000555	0.00142	CcSEcCtD
Quinidine barbiturate—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000554	0.00142	CcSEcCtD
Quinidine barbiturate—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.00055	0.00141	CcSEcCtD
Quinidine barbiturate—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000549	0.0014	CcSEcCtD
Quinidine barbiturate—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000549	0.0014	CcSEcCtD
Quinidine barbiturate—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000548	0.0014	CcSEcCtD
Quinidine barbiturate—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000548	0.0014	CcSEcCtD
Quinidine barbiturate—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000544	0.00139	CcSEcCtD
Quinidine barbiturate—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.00054	0.00138	CcSEcCtD
Quinidine barbiturate—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000537	0.00137	CcSEcCtD
Quinidine barbiturate—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000535	0.00137	CcSEcCtD
Quinidine barbiturate—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000532	0.00136	CcSEcCtD
Quinidine barbiturate—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000532	0.00136	CcSEcCtD
Quinidine barbiturate—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00053	0.00136	CcSEcCtD
Quinidine barbiturate—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000527	0.00135	CcSEcCtD
Quinidine barbiturate—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000527	0.00135	CcSEcCtD
Quinidine barbiturate—Pain—Formoterol—chronic obstructive pulmonary disease	0.000527	0.00135	CcSEcCtD
Quinidine barbiturate—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000527	0.00135	CcSEcCtD
Quinidine barbiturate—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000521	0.00133	CcSEcCtD
Quinidine barbiturate—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000519	0.00133	CcSEcCtD
Quinidine barbiturate—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000517	0.00132	CcSEcCtD
Quinidine barbiturate—Pain—Montelukast—chronic obstructive pulmonary disease	0.000516	0.00132	CcSEcCtD
Quinidine barbiturate—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000515	0.00132	CcSEcCtD
Quinidine barbiturate—Purpura—Prednisone—chronic obstructive pulmonary disease	0.000512	0.00131	CcSEcCtD
Quinidine barbiturate—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000511	0.0013	CcSEcCtD
Quinidine barbiturate—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.00051	0.0013	CcSEcCtD
Quinidine barbiturate—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000508	0.0013	CcSEcCtD
Quinidine barbiturate—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000508	0.0013	CcSEcCtD
Quinidine barbiturate—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000507	0.0013	CcSEcCtD
Quinidine barbiturate—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000506	0.00129	CcSEcCtD
Quinidine barbiturate—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000505	0.00129	CcSEcCtD
Quinidine barbiturate—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000504	0.00129	CcSEcCtD
Quinidine barbiturate—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000504	0.00129	CcSEcCtD
Quinidine barbiturate—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.000504	0.00129	CcSEcCtD
Quinidine barbiturate—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000502	0.00128	CcSEcCtD
Quinidine barbiturate—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000498	0.00127	CcSEcCtD
Quinidine barbiturate—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000498	0.00127	CcSEcCtD
Quinidine barbiturate—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000494	0.00126	CcSEcCtD
Quinidine barbiturate—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.00049	0.00125	CcSEcCtD
Quinidine barbiturate—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.00049	0.00125	CcSEcCtD
Quinidine barbiturate—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000487	0.00125	CcSEcCtD
Quinidine barbiturate—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000487	0.00125	CcSEcCtD
Quinidine barbiturate—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000487	0.00125	CcSEcCtD
Quinidine barbiturate—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000487	0.00125	CcSEcCtD
Quinidine barbiturate—Affect lability—Prednisone—chronic obstructive pulmonary disease	0.000486	0.00124	CcSEcCtD
Quinidine barbiturate—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000486	0.00124	CcSEcCtD
Quinidine barbiturate—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000481	0.00123	CcSEcCtD
Quinidine barbiturate—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000481	0.00123	CcSEcCtD
Quinidine barbiturate—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000481	0.00123	CcSEcCtD
Quinidine barbiturate—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.00048	0.00123	CcSEcCtD
Quinidine barbiturate—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.00048	0.00123	CcSEcCtD
Quinidine barbiturate—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000478	0.00122	CcSEcCtD
Quinidine barbiturate—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000478	0.00122	CcSEcCtD
Quinidine barbiturate—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000477	0.00122	CcSEcCtD
Quinidine barbiturate—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000477	0.00122	CcSEcCtD
Quinidine barbiturate—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000476	0.00122	CcSEcCtD
Quinidine barbiturate—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000472	0.00121	CcSEcCtD
Quinidine barbiturate—Irritability—Prednisone—chronic obstructive pulmonary disease	0.000471	0.0012	CcSEcCtD
Quinidine barbiturate—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.00047	0.0012	CcSEcCtD
Quinidine barbiturate—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	0.000469	0.0012	CcSEcCtD
Quinidine barbiturate—KCNK1—Neuronal System—CHRNA5—chronic obstructive pulmonary disease	0.000469	0.0343	CbGpPWpGaD
Quinidine barbiturate—Mood swings—Prednisone—chronic obstructive pulmonary disease	0.000467	0.00119	CcSEcCtD
Quinidine barbiturate—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000462	0.00118	CcSEcCtD
Quinidine barbiturate—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.00046	0.00118	CcSEcCtD
Quinidine barbiturate—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.00046	0.00118	CcSEcCtD
Quinidine barbiturate—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000454	0.00116	CcSEcCtD
Quinidine barbiturate—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000454	0.00116	CcSEcCtD
Quinidine barbiturate—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000454	0.00116	CcSEcCtD
Quinidine barbiturate—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000453	0.00116	CcSEcCtD
Quinidine barbiturate—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000445	0.00114	CcSEcCtD
Quinidine barbiturate—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000442	0.00113	CcSEcCtD
Quinidine barbiturate—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000442	0.00113	CcSEcCtD
Quinidine barbiturate—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000436	0.00111	CcSEcCtD
Quinidine barbiturate—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000436	0.00111	CcSEcCtD
Quinidine barbiturate—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000435	0.00111	CcSEcCtD
Quinidine barbiturate—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000433	0.00111	CcSEcCtD
Quinidine barbiturate—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000429	0.0011	CcSEcCtD
Quinidine barbiturate—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000427	0.00109	CcSEcCtD
Quinidine barbiturate—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000422	0.00108	CcSEcCtD
Quinidine barbiturate—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000422	0.00108	CcSEcCtD
Quinidine barbiturate—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000417	0.00107	CcSEcCtD
Quinidine barbiturate—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000413	0.00106	CcSEcCtD
Quinidine barbiturate—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000412	0.00105	CcSEcCtD
Quinidine barbiturate—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000409	0.00105	CcSEcCtD
Quinidine barbiturate—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000408	0.00104	CcSEcCtD
Quinidine barbiturate—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000408	0.00104	CcSEcCtD
Quinidine barbiturate—GABRA2—Ion channel transport—ATP2C2—chronic obstructive pulmonary disease	0.0004	0.0293	CbGpPWpGaD
Quinidine barbiturate—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000399	0.00102	CcSEcCtD
Quinidine barbiturate—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000399	0.00102	CcSEcCtD
Quinidine barbiturate—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000398	0.00102	CcSEcCtD
Quinidine barbiturate—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000392	0.001	CcSEcCtD
Quinidine barbiturate—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000392	0.001	CcSEcCtD
Quinidine barbiturate—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000389	0.000993	CcSEcCtD
Quinidine barbiturate—Rash—Formoterol—chronic obstructive pulmonary disease	0.000389	0.000993	CcSEcCtD
Quinidine barbiturate—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000388	0.000992	CcSEcCtD
Quinidine barbiturate—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000388	0.000992	CcSEcCtD
Quinidine barbiturate—Headache—Formoterol—chronic obstructive pulmonary disease	0.000386	0.000987	CcSEcCtD
Quinidine barbiturate—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000386	0.000987	CcSEcCtD
Quinidine barbiturate—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000385	0.000985	CcSEcCtD
Quinidine barbiturate—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000385	0.000984	CcSEcCtD
Quinidine barbiturate—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000384	0.000981	CcSEcCtD
Quinidine barbiturate—KCNK1—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	0.000382	0.028	CbGpPWpGaD
Quinidine barbiturate—Rash—Montelukast—chronic obstructive pulmonary disease	0.000381	0.000973	CcSEcCtD
Quinidine barbiturate—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.00038	0.000972	CcSEcCtD
Quinidine barbiturate—Headache—Montelukast—chronic obstructive pulmonary disease	0.000378	0.000967	CcSEcCtD
Quinidine barbiturate—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000374	0.000955	CcSEcCtD
Quinidine barbiturate—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.00037	0.000946	CcSEcCtD
Quinidine barbiturate—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000367	0.000939	CcSEcCtD
Quinidine barbiturate—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000367	0.000938	CcSEcCtD
Quinidine barbiturate—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000367	0.000937	CcSEcCtD
Quinidine barbiturate—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000367	0.000937	CcSEcCtD
Quinidine barbiturate—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000366	0.000936	CcSEcCtD
Quinidine barbiturate—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000366	0.000936	CcSEcCtD
Quinidine barbiturate—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000365	0.000932	CcSEcCtD
Quinidine barbiturate—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000359	0.000919	CcSEcCtD
Quinidine barbiturate—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000359	0.000916	CcSEcCtD
Quinidine barbiturate—GABRA2—Ion channel transport—TRPV4—chronic obstructive pulmonary disease	0.000357	0.0261	CbGpPWpGaD
Quinidine barbiturate—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000354	0.000906	CcSEcCtD
Quinidine barbiturate—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000348	0.000888	CcSEcCtD
Quinidine barbiturate—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000346	0.000883	CcSEcCtD
Quinidine barbiturate—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000343	0.000877	CcSEcCtD
Quinidine barbiturate—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000341	0.000873	CcSEcCtD
Quinidine barbiturate—GABRA1—Ion channel transport—ATP2C2—chronic obstructive pulmonary disease	0.000341	0.025	CbGpPWpGaD
Quinidine barbiturate—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.00034	0.000868	CcSEcCtD
Quinidine barbiturate—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000334	0.000853	CcSEcCtD
Quinidine barbiturate—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000328	0.000839	CcSEcCtD
Quinidine barbiturate—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000326	0.000833	CcSEcCtD
Quinidine barbiturate—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000323	0.000825	CcSEcCtD
Quinidine barbiturate—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000319	0.000815	CcSEcCtD
Quinidine barbiturate—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000317	0.00081	CcSEcCtD
Quinidine barbiturate—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000308	0.000788	CcSEcCtD
Quinidine barbiturate—GABRA1—Ion channel transport—TRPV4—chronic obstructive pulmonary disease	0.000304	0.0223	CbGpPWpGaD
Quinidine barbiturate—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000299	0.000764	CcSEcCtD
Quinidine barbiturate—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000297	0.00076	CcSEcCtD
Quinidine barbiturate—Erythema—Prednisone—chronic obstructive pulmonary disease	0.000297	0.00076	CcSEcCtD
Quinidine barbiturate—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000285	0.000729	CcSEcCtD
Quinidine barbiturate—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.00028	0.000716	CcSEcCtD
Quinidine barbiturate—GRIA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA5—chronic obstructive pulmonary disease	0.000278	0.0204	CbGpPWpGaD
Quinidine barbiturate—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000275	0.000703	CcSEcCtD
Quinidine barbiturate—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000273	0.000698	CcSEcCtD
Quinidine barbiturate—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000272	0.000694	CcSEcCtD
Quinidine barbiturate—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000267	0.000682	CcSEcCtD
Quinidine barbiturate—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000266	0.000681	CcSEcCtD
Quinidine barbiturate—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000265	0.000678	CcSEcCtD
Quinidine barbiturate—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000261	0.000668	CcSEcCtD
Quinidine barbiturate—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000257	0.000658	CcSEcCtD
Quinidine barbiturate—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000253	0.000647	CcSEcCtD
Quinidine barbiturate—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000253	0.000647	CcSEcCtD
Quinidine barbiturate—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000252	0.000644	CcSEcCtD
Quinidine barbiturate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000251	0.000642	CcSEcCtD
Quinidine barbiturate—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000246	0.000628	CcSEcCtD
Quinidine barbiturate—CYP2D6—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000245	0.018	CbGpPWpGaD
Quinidine barbiturate—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000243	0.00062	CcSEcCtD
Quinidine barbiturate—Shock—Prednisone—chronic obstructive pulmonary disease	0.000239	0.00061	CcSEcCtD
Quinidine barbiturate—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000238	0.000608	CcSEcCtD
Quinidine barbiturate—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000237	0.000605	CcSEcCtD
Quinidine barbiturate—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000236	0.000602	CcSEcCtD
Quinidine barbiturate—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000234	0.000599	CcSEcCtD
Quinidine barbiturate—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000231	0.000591	CcSEcCtD
Quinidine barbiturate—GRIA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA3—chronic obstructive pulmonary disease	0.000227	0.0166	CbGpPWpGaD
Quinidine barbiturate—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000221	0.000565	CcSEcCtD
Quinidine barbiturate—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000221	0.000564	CcSEcCtD
Quinidine barbiturate—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000211	0.000539	CcSEcCtD
Quinidine barbiturate—Rash—Prednisolone—chronic obstructive pulmonary disease	0.00021	0.000538	CcSEcCtD
Quinidine barbiturate—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.00021	0.000537	CcSEcCtD
Quinidine barbiturate—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000209	0.000534	CcSEcCtD
Quinidine barbiturate—GRIA2—Transmission across Chemical Synapses—CHRNA5—chronic obstructive pulmonary disease	0.000209	0.0153	CbGpPWpGaD
Quinidine barbiturate—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000207	0.00053	CcSEcCtD
Quinidine barbiturate—CYP2D6—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000205	0.015	CbGpPWpGaD
Quinidine barbiturate—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.0002	0.000511	CcSEcCtD
Quinidine barbiturate—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000198	0.000507	CcSEcCtD
Quinidine barbiturate—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000198	0.000507	CcSEcCtD
Quinidine barbiturate—CHRM2—Monoamine GPCRs—ADRB2—chronic obstructive pulmonary disease	0.000197	0.0145	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000197	0.0144	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA5—chronic obstructive pulmonary disease	0.000196	0.0143	CbGpPWpGaD
Quinidine barbiturate—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000193	0.000492	CcSEcCtD
Quinidine barbiturate—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000192	0.00049	CcSEcCtD
Quinidine barbiturate—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000192	0.00049	CcSEcCtD
Quinidine barbiturate—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000179	0.000457	CcSEcCtD
Quinidine barbiturate—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000178	0.013	CbGpPWpGaD
Quinidine barbiturate—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000174	0.000445	CcSEcCtD
Quinidine barbiturate—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000172	0.000439	CcSEcCtD
Quinidine barbiturate—GRIA2—Transmission across Chemical Synapses—CHRNA3—chronic obstructive pulmonary disease	0.00017	0.0125	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA5—chronic obstructive pulmonary disease	0.000167	0.0122	CbGpPWpGaD
Quinidine barbiturate—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000166	0.000424	CcSEcCtD
Quinidine barbiturate—CHRM2—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	0.000166	0.0122	CbGpPWpGaD
Quinidine barbiturate—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.00016	0.00041	CcSEcCtD
Quinidine barbiturate—GRIA2—Neuronal System—CHRNA5—chronic obstructive pulmonary disease	0.00016	0.0117	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA3—chronic obstructive pulmonary disease	0.00016	0.0117	CbGpPWpGaD
Quinidine barbiturate—SCN5A—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.000156	0.0114	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	0.000154	0.0113	CbGpPWpGaD
Quinidine barbiturate—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000154	0.000394	CcSEcCtD
Quinidine barbiturate—Rash—Prednisone—chronic obstructive pulmonary disease	0.000153	0.000391	CcSEcCtD
Quinidine barbiturate—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000153	0.00039	CcSEcCtD
Quinidine barbiturate—CYP2D6—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	0.000152	0.0112	CbGpPWpGaD
Quinidine barbiturate—Headache—Prednisone—chronic obstructive pulmonary disease	0.000152	0.000388	CcSEcCtD
Quinidine barbiturate—KCNH2—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.000151	0.0111	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000149	0.0109	CbGpPWpGaD
Quinidine barbiturate—KCNH2—Hematopoietic Stem Cell Differentiation—IL1B—chronic obstructive pulmonary disease	0.000147	0.0108	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmission across Chemical Synapses—CHRNA5—chronic obstructive pulmonary disease	0.000147	0.0108	CbGpPWpGaD
Quinidine barbiturate—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000144	0.000368	CcSEcCtD
Quinidine barbiturate—CYP2D6—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000143	0.0105	CbGpPWpGaD
Quinidine barbiturate—KCNH2—Neuronal System—CHRNA5—chronic obstructive pulmonary disease	0.000141	0.0104	CbGpPWpGaD
Quinidine barbiturate—SCN5A—SIDS Susceptibility Pathways—SLC6A4—chronic obstructive pulmonary disease	0.000141	0.0103	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCRs, Other—CXCR2—chronic obstructive pulmonary disease	0.00014	0.0102	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000139	0.0102	CbGpPWpGaD
Quinidine barbiturate—KCNH2—SIDS Susceptibility Pathways—SLC6A4—chronic obstructive pulmonary disease	0.000136	0.01	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA3—chronic obstructive pulmonary disease	0.000136	0.00997	CbGpPWpGaD
Quinidine barbiturate—GRIA2—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	0.000131	0.00956	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.00013	0.0095	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmission across Chemical Synapses—CHRNA5—chronic obstructive pulmonary disease	0.000125	0.00919	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000124	0.00909	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmission across Chemical Synapses—CHRNA3—chronic obstructive pulmonary disease	0.00012	0.00879	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000119	0.0087	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000118	0.00865	CbGpPWpGaD
Quinidine barbiturate—KCNH2—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	0.000115	0.00845	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Neuronal System—CHRNA5—chronic obstructive pulmonary disease	0.000113	0.00826	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000111	0.00811	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000106	0.00775	CbGpPWpGaD
Quinidine barbiturate—GABRA1—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.000103	0.00753	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmission across Chemical Synapses—CHRNA3—chronic obstructive pulmonary disease	0.000102	0.00749	CbGpPWpGaD
Quinidine barbiturate—SCN5A—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	9.76e-05	0.00715	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Neuronal System—CHRNA5—chronic obstructive pulmonary disease	9.61e-05	0.00704	CbGpPWpGaD
Quinidine barbiturate—KCNH2—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	9.46e-05	0.00693	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Cardiac Progenitor Differentiation—TGFB1—chronic obstructive pulmonary disease	9.43e-05	0.00691	CbGpPWpGaD
Quinidine barbiturate—GABRA1—SIDS Susceptibility Pathways—SLC6A4—chronic obstructive pulmonary disease	9.27e-05	0.00679	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	9.19e-05	0.00673	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCRs, Other—ADRB2—chronic obstructive pulmonary disease	8.77e-05	0.00642	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	8.71e-05	0.00638	CbGpPWpGaD
Quinidine barbiturate—SCN5A—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	8.63e-05	0.00633	CbGpPWpGaD
Quinidine barbiturate—KCNH2—Hematopoietic Stem Cell Differentiation—IL6—chronic obstructive pulmonary disease	8.63e-05	0.00632	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	8.51e-05	0.00624	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	8.4e-05	0.00616	CbGpPWpGaD
Quinidine barbiturate—KCNH2—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	8.37e-05	0.00613	CbGpPWpGaD
Quinidine barbiturate—CHRM2—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	8.04e-05	0.00589	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	7.84e-05	0.00574	CbGpPWpGaD
Quinidine barbiturate—CHRM2—SIDS Susceptibility Pathways—SLC6A4—chronic obstructive pulmonary disease	7.26e-05	0.00532	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	6.9e-05	0.00506	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCRs, Other—HTR2A—chronic obstructive pulmonary disease	6.85e-05	0.00502	CbGpPWpGaD
Quinidine barbiturate—CHRM2—G alpha (i) signalling events—CXCR2—chronic obstructive pulmonary disease	6.54e-05	0.00479	CbGpPWpGaD
Quinidine barbiturate—GABRA1—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	6.43e-05	0.00471	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	6.19e-05	0.00453	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	6.1e-05	0.00447	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	6.07e-05	0.00445	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Calcium Regulation in the Cardiac Cell—ADRB2—chronic obstructive pulmonary disease	5.91e-05	0.00433	CbGpPWpGaD
Quinidine barbiturate—SCN5A—L1CAM interactions—EGFR—chronic obstructive pulmonary disease	5.75e-05	0.00421	CbGpPWpGaD
Quinidine barbiturate—GABRA1—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	5.69e-05	0.00417	CbGpPWpGaD
Quinidine barbiturate—SCN5A—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	5.33e-05	0.00391	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	5.2e-05	0.00381	CbGpPWpGaD
Quinidine barbiturate—KCNH2—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	5.17e-05	0.00379	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Developmental Biology—ADIPOQ—chronic obstructive pulmonary disease	5.14e-05	0.00376	CbGpPWpGaD
Quinidine barbiturate—SCN5A—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	5.12e-05	0.00375	CbGpPWpGaD
Quinidine barbiturate—CHRM2—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	5.03e-05	0.00369	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	5.02e-05	0.00367	CbGpPWpGaD
Quinidine barbiturate—KCNH2—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	4.96e-05	0.00363	CbGpPWpGaD
Quinidine barbiturate—CHRM2—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	4.45e-05	0.00326	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	4.41e-05	0.00323	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	4.36e-05	0.00319	CbGpPWpGaD
Quinidine barbiturate—SCN5A—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	4.33e-05	0.00317	CbGpPWpGaD
Quinidine barbiturate—KCNH2—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	4.2e-05	0.00308	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	3.96e-05	0.0029	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	3.81e-05	0.00279	CbGpPWpGaD
Quinidine barbiturate—SCN5A—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	3.71e-05	0.00272	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	3.67e-05	0.00269	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.62e-05	0.00265	CbGpPWpGaD
Quinidine barbiturate—KCNH2—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	3.6e-05	0.00264	CbGpPWpGaD
Quinidine barbiturate—GABRA1—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	3.51e-05	0.00257	CbGpPWpGaD
Quinidine barbiturate—GABRA1—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	3.37e-05	0.00247	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	3.26e-05	0.00239	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	3.25e-05	0.00238	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Developmental Biology—LEP—chronic obstructive pulmonary disease	3.19e-05	0.00234	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.06e-05	0.00224	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.02e-05	0.00221	CbGpPWpGaD
Quinidine barbiturate—SCN5A—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	3e-05	0.0022	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	2.98e-05	0.00218	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	2.92e-05	0.00214	CbGpPWpGaD
Quinidine barbiturate—KCNH2—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	2.9e-05	0.00213	CbGpPWpGaD
Quinidine barbiturate—GABRA1—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	2.85e-05	0.00209	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.81e-05	0.00206	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	2.78e-05	0.00203	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.77e-05	0.00203	CbGpPWpGaD
Quinidine barbiturate—CHRM2—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	2.75e-05	0.00202	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	2.73e-05	0.002	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Axon guidance—MMP9—chronic obstructive pulmonary disease	2.69e-05	0.00197	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.66e-05	0.00195	CbGpPWpGaD
Quinidine barbiturate—CHRM2—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	2.64e-05	0.00193	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.63e-05	0.00192	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	2.55e-05	0.00187	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	2.52e-05	0.00185	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	2.49e-05	0.00182	CbGpPWpGaD
Quinidine barbiturate—GABRA1—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	2.45e-05	0.00179	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Axon guidance—VEGFA—chronic obstructive pulmonary disease	2.41e-05	0.00177	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	2.33e-05	0.00171	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	2.24e-05	0.00164	CbGpPWpGaD
Quinidine barbiturate—CHRM2—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	2.23e-05	0.00164	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	2.22e-05	0.00163	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Axon guidance—EGFR—chronic obstructive pulmonary disease	2.17e-05	0.00159	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	2.14e-05	0.00157	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Regulation of Actin Cytoskeleton—EGFR—chronic obstructive pulmonary disease	2.09e-05	0.00153	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	2.03e-05	0.00149	CbGpPWpGaD
Quinidine barbiturate—CHRM2—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	1.98e-05	0.00145	CbGpPWpGaD
Quinidine barbiturate—GABRA1—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	1.97e-05	0.00145	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	1.97e-05	0.00144	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	1.94e-05	0.00142	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Developmental Biology—MMP9—chronic obstructive pulmonary disease	1.92e-05	0.00141	CbGpPWpGaD
Quinidine barbiturate—CHRM2—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	1.92e-05	0.0014	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	1.72e-05	0.00126	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Axon guidance—IL6—chronic obstructive pulmonary disease	1.67e-05	0.00122	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.64e-05	0.0012	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	1.58e-05	0.00116	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	1.58e-05	0.00115	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Developmental Biology—EGFR—chronic obstructive pulmonary disease	1.55e-05	0.00114	CbGpPWpGaD
Quinidine barbiturate—CHRM2—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	1.55e-05	0.00113	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	1.49e-05	0.00109	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Developmental Biology—TNF—chronic obstructive pulmonary disease	1.48e-05	0.00108	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.42e-05	0.00104	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.4e-05	0.00103	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.4e-05	0.00102	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	1.38e-05	0.00101	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.28e-05	0.000941	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.28e-05	0.000934	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.26e-05	0.000919	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.2e-05	0.00088	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.2e-05	0.000879	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Developmental Biology—IL6—chronic obstructive pulmonary disease	1.19e-05	0.000873	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.14e-05	0.000835	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.1e-05	0.000804	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	9.97e-06	0.00073	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	8.78e-06	0.000643	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—KL—chronic obstructive pulmonary disease	8.16e-06	0.000598	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.54e-06	0.000553	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	7.53e-06	0.000552	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	7.46e-06	0.000546	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	6.81e-06	0.000499	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	6.78e-06	0.000497	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	6.73e-06	0.000493	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.27e-06	0.000459	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	6.16e-06	0.000451	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	6.12e-06	0.000448	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	5.89e-06	0.000432	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.48e-06	0.000401	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.23e-06	0.000383	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.16e-06	0.000378	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.81e-06	0.000352	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.56e-06	0.000334	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.5e-06	0.00033	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.3e-06	0.000315	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.1e-06	0.000301	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.64e-06	0.000267	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.46e-06	0.000253	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.29e-06	0.000241	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	3.1e-06	0.000227	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	2.96e-06	0.000217	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.96e-06	0.000217	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.71e-06	0.000199	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.66e-06	0.000195	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.23e-06	0.000164	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.04e-06	0.00015	CbGpPWpGaD
